Journal
CANCER CAUSES & CONTROL
Volume 24, Issue 5, Pages 961-977Publisher
SPRINGER
DOI: 10.1007/s10552-013-0172-6
Keywords
Colorectal cancer; Delayed diagnosis; Time factors; Outcomes; Survival; SEER-medicare
Funding
- National Cancer Institute [CA112159]
- National Center for Research Resources Washington University-ICTS [KL2 RR024994]
- Health Behavior, Communication and Outreach Core
- National Cancer Institute Cancer Center [P30 CA91842]
- Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis, Missouri
- DK-56260, HL-38180
- DDRCC DK-52574
Ask authors/readers for more resources
Using 1998-2005 SEER-Medicare data, we examined the effect of diagnostic and treatment delays on all-cause and colorectal cancer (CRC)-specific death among US adults aged a parts per thousand yen 66 years with invasive colon or rectal cancer. We hypothesized that longer delays would be associated with a greater risk of death. We defined diagnostic and treatment delays, respectively, as days between (1) initial medical consult for CRC symptoms and pathologically confirmed diagnosis (maximum: 365 days) and (2) pathologically confirmed diagnosis and treatment (maximum: 120 days). Cases (CRC deaths) and controls (deaths due to other causes or censored) were matched on survival time. Logistic regression analyses adjusted for sociodemographic, tumor, and treatment factors. Median diagnostic delays were 60 (colon) and 40 (rectal) days and treatment delays were 13 (colon) and 16 (rectal) days in 10,663 patients. Colon cancer patients with the longest diagnostic delays (8-12 months vs. 14-59 days) had higher odds of all-cause (aOR: 1.31 CI: 1.08-1.58), but not CRC-specific death. Colon cancer patients with the shortest treatment delays (< 1 vs. 1-2 weeks) had higher odds of all-cause (aOR: 1.23 CI: 1.01-1.49), but not CRC-specific death. Among rectal cancer patients, delays were not associated with risk of all-cause or CRC-specific death. Longer delays of up to 1 year after symptom onset and 120 days for treatment did not increase odds of CRC-specific death. There may be little clinical benefit in detecting and treating existing symptomatic disease earlier. Screening prior to symptom onset must remain the primary goal to reduce CRC incidence, morbidity, and mortality.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available